Do you ever repeat screening for acquired von Willebrand in patients with essential thrombocythemia who have high platelet counts and very low risk disease not on cytoreductive therapy?
Such as in a patient with essential thrombocythemia with a CALR mutation, younger than age 60, no history of thrombosis, no bleeding or vasomotor symptoms, normal spleen size, and platelet count over 1,000,000,000 who underwent screening tests for acquired von Willebrand with ristocetin cofactor activity > 40%. Would you repeat testing in the absence of bleeding symptoms? If so, when/how often?
Answer from: at Academic Institution
I generally check on a regular basis (i.e., yearly) to confirm no changes. Obviously, if there is bleeding I would check at that time.
Sign in or Register to read more